{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-003670","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.287963+00:00","generated_at":"2026-06-20T18:44:04.821732+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Aura Biosciences updates corporate presentation for J.P. Morgan Healthcare Conference","bullets":["Attending 41st Annual J.P. Morgan Healthcare Conference starting January 9, 2023 in San Francisco.","Updated corporate presentation filed as Exhibit 99.1 for investor meetings.","Forward-looking statements caution about risks including clinical trials and regulatory approvals.","Company's product candidate belzupacap sarotalocan for choroidal melanoma is highlighted."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-003670","json":"https://secwatch.observer/filing/0001193125-23-003670.json","markdown":"https://secwatch.observer/filing/0001193125-23-003670.md","text":"https://secwatch.observer/filing/0001193125-23-003670.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000119312523003670/0001193125-23-003670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000119312523003670/d377715d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:44:04.821732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}